Nitroxide Peptide Conjugate for Targeting Akt Nitration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary arterial hypertension (PAH) are largely ineffective, and existing antioxidant therapies have global cellular effects without clinical significance, failing to address the specific pathological processes involved in the disease, particularly the nitration of Akt protein which contributes to vascular remodeling and proliferation.
Innovation Solution
A targeted peptide conjugated with an antioxidant nitroxide moiety, specifically designed to inhibit Akt nitration at the Tyr 350 residue, which prevents protein oxidation and maintains glucose influx without affecting Akt phosphorylation or other physiological processes, thereby addressing the root cause of PAH and related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If global antioxidant therapy is used, then oxidative stress is reduced, but clinical significance is not achieved due to lack of targeted effect
Solution Approach 1:
The patent applies local quality by designing an antioxidant peptide with a specific amino acid sequence (Ser-Arg-Leu-Arg-Ser) that confers affinity to the Akt protein at the nitration site. This localized targeting to the specific protein site (Tyr 350 residue) transforms the non-specific global antioxidant approach into a targeted therapy that selectively protects Akt from nitration while maintaining other physiological processes
Solution Approach 2:
The antioxidant peptide acts as an intermediary between the harmful nitrating species and the Akt protein. The peptide sequence serves as a mediator that binds to the nitration site on Akt, intercepting the damaging effect before it can modify the protein, thereby protecting Akt specifically without affecting other cellular processes
2Object-affected harmful factors
If Akt nitration is inhibited, then vascular proliferation is controlled, but other Akt-mediated physiological processes may be affected
Solution Approach 1:
The antioxidant peptide with sequence Ser-Arg-Leu-Arg-Ser is designed to bind specifically to the nitration site (Tyr 350) on Akt, providing localized protection only at this specific residue. This localized action selectively prevents nitration-induced vascular proliferation while allowing other Akt phosphorylation sites and physiological processes to continue normally
Solution Approach 2:
The invention converts the harmful effect of nitration into a beneficial targeted protection mechanism. By using an antioxidant peptide that specifically binds to the nitration site, the harmful nitrating species are effectively neutralized at the source, transforming the pathological nitration process into a controlled protective mechanism that prevents damage without interfering with normal Akt function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide effectively reduces Akt nitration, attenuates right ventricular hypertrophy, lowers pulmonary arterial pressure, and reverses metabolic reprogramming from glycolysis to oxidative phosphorylation, thereby controlling vascular proliferation and improving pulmonary function in PAH.
Implementation Method 1
Nitroxides are the family of free radical compounds, which are effective scavengers of reactive oxygen species (ROS). These properties make nitroxide suitable for the development of defensive peptides for preventing Akt nitration.
Implementation Method 2
Nitroxides function as a superoxide dismutase (SOD) mimetic, performing the interconversion of an oxammonium cation or the hydroxylamine.
Implementation Method 3
The affinity peptide of the present invention that is exclusively targeted to protect the Akt nitration site, is conjugated with nitroxide moiety forming nitroxide-peptide (NP). Specifically, this would block the tyrosine (Tyr)-350 nitration of Akt
Data Source
AI summary
The present invention is a targeted peptide conjugated with an antioxidant, NO, to inhibit Akt nitration. The nitroxide peptide (NP), comprises two parts, one being the peptide part with the affinity to Akt near Tyr 350 residue (Ser-Arg-IIe-Arg-Ser; SRIRS)—and the other, a conjugated antioxidant—nitroxide (3-Carboxy-2,2,5,5-tetramethyl-3-pyrroline-1-yloxy) covalently attached to the free N-terminal amine. It can be utilized for treating pulmonary arterial hypertension (PAH) with potential application in other abnormal proliferative disorders such as cancer. The present invention features targeted selectivity for Akt nitration and does not affect Akt phosphorylation nor other physiological processes controlled by Akt signaling pathways. The present invention may also apply to other proliferative disorders including cancer or other disorders that cause or are caused by Akt nitration or protein oxidation.